500 Job Source
drug research company.
One Amgen Center Dr.
Thousand Oaks, CA 91320
CEO: Robert Bradway
Stock Symbol: AMGN
Amgen is the world's largest biotechnology company with presence in 50 countries. Amgen has research programs in inflammation, metabolic disorders and osteoporosis, neurology, oncology and hematology. The company has R&D facilities in Thousand Oaks, CA; San Francisco, CA; Cambridge, MA; Cambridge, UK; Regensburg, Germany; and Seattle, WA.
Products developed by Amgen include: Epogen, used for patients in dialysis with anemia; Neulasta and Neupogen, which decrease infection in patients undergoing chemotheraphy; Enbrel, used to treat forms of arthritis; Aranesp and Sensipar, used to treat problems associated with kidney disease.
Amgen is a global leader in biotechnology
manufacturing, producing more than a third of the world's output
of non-vaccine and non-insulin protein therapeutics.
In 2014, Amgen reported revenues of $20.1 billion, an increase of 7%, and net income of $5.15 billion. Neulasta/Neupogen and Enbrel were the top selling drugs at the company. Neulasta sales increased by 5% mainly due to price. Neupogen sales declined 17% for the year. Enbrel sales increased 3%. The company spent approximately $4.12 billion last year on research and development.
The company's R&D facilities are located in South San Francisco and Thousand Oaks, CA; Cambridge and Woburn, MA; Seattle, WA; Burnaby, British Columbia, Canada; Abingdon, Cambridge, and Uxbridge, UK; Shanghai, China; Regensburg, Germany; and clinical development offices in additional locations around the world.
In November 2014, the company officially opened its Shanghai research facility in China.
AMGen (Applied Molecular Genetics Inc.)
was established as a California corporation on April 8, 1980.
The company changed its name to Amgen in 1983 and went public
Amgen offers generous benefits to employees
Comprehensive, affordable health
care coverage is one of the cornerstones of Amgen's benefits
program. We offer medical, prescription drug, and vision coverage;
dental benefits; and access to our Personal Effectiveness Program
(PEP). This coverage helps our staff members to protect themselves
and their family, stay healthy and balance the demands of work
Amgen provides staff members and their families with protection
from the unexpected. We offer personal and family illness coverage,
disability benefits and basic life insurance. Individuals can
also opt to participate in voluntary options, such as voluntary
life insurance and accidental death and dismemberment insurance.
Amgen knows it can be challenging to balance commitments and priorities. For that reason, we offer U.S. staff generous vacation time and 17 paid holidays annually, as well as adoption and leave-of-absence benefits. Amgen also supports the educational priorities of our staff through a generous education reimbursement plan.
Amgen encourages our staff members to save for the future.
The company contributes an amount equal to five percent of every
paycheck to each individual's Amgen Retirement and Savings Plan,
whether or not the staff member is contributing to the Plan.
In addition, Amgen matches 100 percent of staff contributions
to the Plan up to five percent of pay. So, if you contribute
at least five percent of your pay to the plan, the total company
contribution is ten percent. Company contributions, as well as
staff contributions, are immediately 100 percent vested.
Staff members can also take advantage of the Employee Stock Purchase
Plan (ESPP) by contributing up to 15 percent of their salary
on an after-tax basis, subject to legal limits, to purchase Amgen
common stock at a discount. Additionally, eligible individuals
can participate in the Supplemental Retirement Plan (SRP) and
Deferred Compensation Plan (DCP).
Amgen believes that having fun and enjoying life are as important
as working hard. We sponsor and participate in numerous extracurricular
teams and hold annual activities including barbeques, chili cook-offs,
summer festivals and Halloween celebrations.
Updated February 5, 2015